Trade-Ideas: Amsurg (AMSG) Is Today's

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Trade-Ideas LLC identified Amsurg ( AMSG) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified Amsurg as such a stock due to the following factors:

  • AMSG has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $31.5 million.
  • AMSG has traded 73,137 shares today.
  • AMSG traded in a range 264.7% of the normal price range with a price range of $3.16.
  • AMSG traded above its daily resistance level (quality: 4 days, meaning that the stock is crossing a resistance level set by the last 4 calendar days. The resistance price is defined by the Price - $0.01 at the time of the signal).

Stocks matching the 'Barbarian at the Gate' criteria are worthwhile stocks to watch for a variety of factors including historical back testing and volatility. Trade-Ideas targets these opportunities because the stock is exhibiting an unusual behavior while displaying positive price action. In this case, the stock crossed an important inflection point; namely, 'resistance' while at the same time the range of the stock's movement in price is more than twice its normal size. This large range foreshadows a possible continuation as the stock moves higher.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in AMSG with the Ticky from Trade-Ideas. See the FREE profile for AMSG NOW at Trade-Ideas

If you liked this article you might like

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

'Mad Money' Lightning Round: Kroger, Dunkin' Brands

Jim Cramer's 'Mad Money' Recap: Trump Trade War Could Hit U.S. Car, Apple iPhone Sales

Analysts' Actions -- Tableau, Nucor, Pfizer, Square and More

Mednax Remains Unlikely Target as Medical Mergers Gain Steam